AIM: Gold nanorods (GNRs), cellular imaging nanoprobes, have been used for drug delivery therapy to immunologically privileged regions in the brain. We demonstrate that nanoplexes formed by electrostatic binding between negatively charged RNA and positively charged GNRs, silence the expression of the target housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) within the CA1 hippocampal region of the rat brain, without showing cytotoxicity. MATERIALS & METHODS: Fluorescence imaging with siRNA(Cy3)GAPDH and dark-field imaging using plasmonic enhanced scattering from GNRs were used to monitor the distribution of the nanoplexes within different neuronal cell types present in the targeted hippocampal region. RESULTS & CONCLUSION: Our results show robust nanoplex uptake and slow release of the fluorescent gene silencer with significant impact on the suppression of GAPDH gene expression (70% gene silencing, >10 days postinjection). The observed gene knockdown using nanoplexes in targeted regions of the brain opens a new era of drug treatment for neurological disorders.
AIM: Gold nanorods (GNRs), cellular imaging nanoprobes, have been used for drug delivery therapy to immunologically privileged regions in the brain. We demonstrate that nanoplexes formed by electrostatic binding between negatively charged RNA and positively charged GNRs, silence the expression of the target housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) within the CA1 hippocampal region of the rat brain, without showing cytotoxicity. MATERIALS & METHODS: Fluorescence imaging with siRNA(Cy3)GAPDH and dark-field imaging using plasmonic enhanced scattering from GNRs were used to monitor the distribution of the nanoplexes within different neuronal cell types present in the targeted hippocampal region. RESULTS & CONCLUSION: Our results show robust nanoplex uptake and slow release of the fluorescent gene silencer with significant impact on the suppression of GAPDH gene expression (70% gene silencing, >10 days postinjection). The observed gene knockdown using nanoplexes in targeted regions of the brain opens a new era of drug treatment for neurological disorders.
Authors: Aleksandar Radonić; Stefanie Thulke; Ian M Mackay; Olfert Landt; Wolfgang Siegert; Andreas Nitsche Journal: Biochem Biophys Res Commun Date: 2004-01-23 Impact factor: 3.575
Authors: Krishnan V Chakravarthy; Adela C Bonoiu; William G Davis; Priya Ranjan; Hong Ding; Rui Hu; J Bradford Bowzard; Earl J Bergey; Jacqueline M Katz; Paul R Knight; Suryaprakash Sambhara; Paras N Prasad Journal: Proc Natl Acad Sci U S A Date: 2010-05-24 Impact factor: 11.205
Authors: Mark E Davis; Jonathan E Zuckerman; Chung Hang J Choi; David Seligson; Anthony Tolcher; Christopher A Alabi; Yun Yen; Jeremy D Heidel; Antoni Ribas Journal: Nature Date: 2010-03-21 Impact factor: 49.962
Authors: Deepak R Thakker; Marcy R Weatherspoon; Jonathan Harrison; Thomas E Keene; Deanna S Lane; William F Kaemmerer; Gregory R Stewart; Lisa L Shafer Journal: Proc Natl Acad Sci U S A Date: 2009-02-25 Impact factor: 11.205
Authors: David J Mc Carthy; Meenakshi Malhotra; Aoife M O'Mahony; John F Cryan; Caitriona M O'Driscoll Journal: Pharm Res Date: 2014-12-02 Impact factor: 4.200
Authors: T A Ignatowski; R Aalinkeel; J L Reynolds; B B Nair; D E Sykes; C P K Gleason; W C Law; M J Mammen; P N Prasad; S A Schwartz; Supriya D Mahajan Journal: J Neuroimmune Pharmacol Date: 2015-01-22 Impact factor: 4.147
Authors: Ming Chen; Michael Zakrewsky; Vivek Gupta; Aaron C Anselmo; Deborah H Slee; John A Muraski; Samir Mitragotri Journal: J Control Release Date: 2014-01-13 Impact factor: 9.776
Authors: Rajiv Kumar; Apurva Kulkarni; Jude Nabulsi; Dattatri K Nagesha; Robert Cormack; Mike G Makrigiorgos; Srinivas Sridhar Journal: Drug Deliv Transl Res Date: 2013-08-01 Impact factor: 4.617